Oppenheimer Reiterates Perform on ACADIA Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jay Olson has reiterated a 'Perform' rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and maintained a $25 price target.
August 04, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst has reiterated a 'Perform' rating on ACADIA Pharmaceuticals and maintained a $25 price target.
The news is directly about ACADIA Pharmaceuticals and its rating by Oppenheimer. The 'Perform' rating and maintained price target suggest that the analyst sees the stock performing as expected in the short term, which is neutral news for the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100